Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

Fig. 2

Disposition of SLS II study participants with regard to CXCL4 measurement during the 24-month trial. FVC measurements were obtained in 51 and 59 participants at 12 months and in 50 and 53 participants at 24 months for the CYC and MMF arms, respectively. CYC cyclophosphamide, MMF mycophenolate, SLS Scleroderma Lung Study

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us